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Since the discovery of levodopa (L-dopa) in 1967, the range of medications available to treat Parkinson’s disease has increased
signiﬁcantly and guidance on the use, eﬃcacy, and safety of thesemedications has evolved. To assess levels of adherence to national
prescribing guidelines and awareness of changes in the eﬃcacy and safety data published in the proﬁles of medications for the
treatment of PD, we have reviewed studies on patterns and determinants of prescribing PD medications conducted in the last 50
years (since the discovery of L-dopa). A systematic literature review was conducted using EMBASE (1967 to March, 2018), Ovid
MEDLINE(R) ALL (1967 to March 16, 2018), PsycINFO (1967 to the 2nd week of March, 2018), and PubMed to identify all studies
measuring prescribing patterns of PD medication between 1967 and 2017. Study design, source of data, country, year of study,
number of patients and/or prescriptions, unit of analysis, prescribing determinants, and percentage utilisation of PD medications
were extracted where possible. 44 studies examining prescribing patterns and/or prescribing determinants across 17 countries
were identiﬁed. Unsurprisingly, L-dopa was the most commonly prescribed medication in all studies, accounting for 46.50% to
100% of all prescriptions for PD. In several studies, the prescribing rate of ergot-derived dopamine agonists (DAs) decreased over
time in concordance with guidance. In contrast, the prescribing rates of non-ergot DAs increased over the last ten years in most of
the included studies. In examining prescribing factors, two major categories were exempliﬁed, patients’ factors and prescribers’
factors, with patients’ age being the most common factor that aﬀected the prescription in most studies. In conclusion, L-dopa is
now the most commonly prescribed medication for cases of PD but there is large variation in the prescribing rates of catechol-O-
methyltransferase (COMT) inhibitors, monoamine oxidase B (MAO-B) inhibitors, amantadine, and anticholinergics between
countries. New studies examining the eﬀects of recent clinical trials and measuring the prescribing rates of newly approved
medications are warranted.
1. Introduction
Since the ﬁrst detailed description of the condition now
known as “Parkinson’s disease” (PD) in 1817, extensive
eﬀorts have been devoted to ﬁnding a cure. In the late 1960s,
George Cotzias described the eﬃcacy and safety of oral
levodopa (L-dopa) in treating the motor symptoms of
Parkinson’s disease. He determined that when the L-dopa
dose was increased gradually, motor symptoms improved
for a longer duration with minimal gastrointestinal adverse
eﬀects [1, 2]. Other compounds were tested alongside
L-dopa, including amantadine, which Schwab et al. [3]
discovered suppressed tremors. Problematically, although
highly eﬀective at treating the motor symptoms, it was
determined early on that L-dopa induces dyskinesia and
motor ﬂuctuations often develop, limiting use of the drug.
,ere remained a need to search for a drug that could
improve motor symptoms without these issues and even
more desirable to have disease-modifying properties [4, 5].
In 1974 (see Figure 1), the ergot dopamine agonist, bro-
mocriptine, was tested, demonstrating a longer half-life than
L-dopa and fewer motor ﬂuctuations [6]. One year later, a
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combination of L-dopa and dopa decarboxylase inhibitor
(carbidopa) reduced the gastrointestinal side eﬀects com-
pared to L-dopa alone [7–9]. ,e safety and eﬃcacy of the
monoamine oxidase B (MAO-B) inhibitor selegiline (dep-
renyl), as an adjunct to L-dopa therapy, was then demon-
strated in 1977 [10]. From 1982 to 1992, several dopamine
agonists (DAs) were introduced to the market, to be used
either as L-dopa adjuncts in patients with long-term com-
plications or as de novo therapy in place of L-dopa [11]. In
1997, tolcapone, catechol-O-methyl transferase inhibitor
(COMT inhibitor) was approved in Europe as a treatment to
reduce the motor ﬂuctuations caused by L-dopa [12]. Since
then, no new pharmacological class has been introduced in
clinical practice; although newer generations of drugs from
established drug classes have been introduced, including
entacapone (COMT inhibitor) (1999), rasagiline (MAO-B
inhibitor) (2005), rotigotine in a patch formulation (non-
ergot dopamine agonist) (2006), saﬁnamide (MAO-B in-
hibitor) (2016), and opicapone (COMT inhibitor) (2016)
[12–16]. Additionally, since the early 2000s, new pharma-
ceutical formulations such as infusion therapies (sub-
cutaneous apomorphine and levodopa-carbidopa intestinal
gel (LCIG)) became available in several countries with the
promise of tackling the motor complications (mainly the
wearing-oﬀ phenomenon) caused by the oral form of L-dopa
in patients with advanced stage of PD [17].
,e perception of the utility of these drugs has evolved
over time and this is reﬂected in subtle changes in the
guidance; for example, DAs and MAO-B inhibitors were
initially purported to have potential neuroprotective prop-
erties leading to their early prescribing following diagnosis
but several clinical trials failed to ﬁnd clear evidence to
support this [18–23]. L-DOPA has been widely compared
with the DAs, including bromocriptine, ropinirole, prami-
pexole, and pergolide; these concluded that initiating
therapy with DAs was associated with delaying dyskinesia
onset or motor ﬂuctuations or both [24–28]. Accordingly,
guidelines recommended starting therapy with DAs rather
than L-dopa, unless the DAs failed to manage the motor
symptoms [29–31] or alternatively commencing therapy
with L-dopa or DAs without preference [30, 32]. ,e impact
of the motor ﬂuctuations caused by L-dopa on patients’
quality of life (QoL) was not clear until 2014 when the PD-
MED study [33] used the quality of life (QoL) scale as a
primary outcome. ,e study’s main ﬁnding was that early
initiation of L-dopa resulted in a better QoL in the long term
than initiating DAs and MAO-B inhibitors [33].
Increased knowledge of eﬃcacy and safety and growing
number of drugs in the market would be expected to impact
prescribing decisions and drug utilisation rates of PD
medications. One means through which adherence to na-
tional prescribing guidelines and awareness of the changes in
eﬃcacy and safety in the medications’ proﬁles can be
evaluated by examining prescribing patterns. Doing so
would help determine the factors that aﬀect prescribing,
including factors such as sex, age, socioeconomic status,
education, and drug pricing [34]. Various studies have been
conducted worldwide and this review draws together pre-
scribing patterns and determinates of PD medication uti-
lisation across the globe to examine the extent to which these
patterns accord with the changes occurring in the safety and
eﬃcacy proﬁles of PD medications.
2. Methods
2.1. Search Strategy. A comprehensive and systematic lit-
erature search was conducted using EMBASE (1947-March,
2018), Ovid MEDLINE(R) ALL (1946 to March 16, 2018),
PsycINFO (1806 to the 2nd week of March, 2018), and
PubMed to identify all studies measuring prescribing
patterns of PD medications (Figure 2). ,e key words used
were “drug utilization” or “prescribing pattern” or
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Figure 1: ,e evolution of pharmacotherapy for Parkinson’s disease with key discoveries in eﬃcacy, safety, and approvals of medications
since the discovery of L-dopa. ,e horizontal line represents years from 1967 to 2017. Coloured boxes around the horizontal line represent
the event type mentioned in the coloured boxes shown in the bottom of the ﬁgure.
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“pharmacoepidemiology” or “prescribing trend” or “in-
appropriate prescribing” or “prescribing factors” or “pre-
scribing determinants” or “prescribing behaviour,”
combined with “Parkinson’s disease” or “idiopathic Par-
kinson’s disease” or “Primary Parkinsonism” or “Paralysis
Agitans” or “Antiparkinson drugs” or “Antiparkinsonians”
or “Antiparkinsonian agents” or “Levodopa” or “L-dopa” or
“dopamine agonists” or “apomorphine” or “cabergoline” or
“lisuride” or “pergolide” or “pramipexole” or “ropinirole” or
“rotigotine” or “amantadine” or “Catechol O-Methyl-
transferase Inhibitors” or “entacapone” or “tolcapone” or
“Monoamine Oxidase Inhibitors” or “rasagiline” or “sele-
giline” or “anticholinergics or “orphenadrine” or “procy-
clidine” or “trihexyphenidyl.” Manual reference research
and Google Scholar were also used in the review (see Part 1
in Supplementary Materials).
2.2. Inclusion and Exclusion Criteria. All English-language
studies that measured the prescribing pattern and/or pre-
scribing and drug utilisation determinants of one or more
than one class of PD medication at any time point were
included in the review. Since the purpose of this review was
to examine all prescribing patterns and determinants
studies, the only exclusion criterion was if the study was
published only as a conference poster. Non-English-lan-
guage studies were excluded from both the main analysis
and the quality assessment due to the lack of translation
resources; however, when possible, the English abstracts of
these studies were screened and obtained (see Parts 2 and 3
in Supplementary Materials).
2.3. Data Extraction, Quality Assessment Checklist, and Data
Analysis. Where information was available, the following
data were extracted from each study: study design, source of
data, country, year of study, number of patients and/or
prescriptions, unit of analysis, prescribing determinants,
main ﬁndings, and utilisation percentages of PD medica-
tions.,e selected studies were classiﬁed into two categories:
studies that examined the prescribing patterns of PD
medications with or without prescribing determinants and
studies that examined prescribing determinants without
measuring prescribing patterns of PD medications.
,e studies selected for this review had heterogeneous
designs which made it diﬃcult to apply the commonly used
quality and reporting assessment checklists for cross-sec-
tional observational studies such as the STROPE checklist
[35] and the National Institutes of Health Quality Assess-
ment Tool for Observational Cohort and Cross-Sectional
Studies [36]. Most published quality and reporting assess-
ment checklists have not been designed to be applied to
pharmacoepidemiological and drug utilisation studies [37].
All the studies selected in this review were descriptive in
nature and did not measure outcomes caused by exposure in
the study participants. For this reason, and to assess and
critique the quality of the selected studies, a critical appraisal
tool that addresses prevalence studies was used [38]. ,is
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Figure 2: PRISMA ﬂow chart for systematic research of prescribing patterns and determinants study.
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tool was chosen as the drug utilisation prevalence of PD
medications is the primary interest of this review. ,e
prevalence of PD medication use was used to estimate the
prevalence of PD itself in several studies [39, 40]; however, in
the current review, it was used solely to study the prescribing
patterns and trends of PD medications. For the purposes of
this review “,e Joanna Briggs Institute Critical Appraisal
Tool for Use in Prevalence Studies” was used (see Part 4 in
Supplementary Materials). ,is tool poses 10 questions
which can be answered by yes, no, unclear, or not applicable.
,e questions relate to the sample representativeness of the
target population, the study participants recruiting method,
the sample size adequacy, the detailed description of study
subjects, the suﬃciency of the coverage of the selected
sample during analysis, the objectivity of the criteria used in
measuring the condition, the reliability of the criteria used to
measure the condition, the appropriateness of the statistical
analysis considering potential confounding factors, and ﬁ-
nally, the objectivity of the criteria used to identify sub-
populations [38].
After obtaining quality score of each study, the
Kruskal–Wallis test was used to compare the prescribing
rates at diﬀerent tiers of quality scores (for this purpose only,
quality scores were classiﬁed into three tiers: from 1 to 3 and
4 to 6, >6). Additionally, a Kruskal–Wallis test also was used
to compare the prescribing rates according to the source of
data. ,e signiﬁcance level was set at P< 0.05 in both tests.
3. Results
3.1. Search Results and Characteristics of the Drug Utilisation
Studies. ,e initial search of the databases used in this
review resulted in the retrieval of 682 studies (see Part 1 in
Supplementary Materials). Twenty-six additional studies
were identiﬁed through other sources (manual reference
research and Google Scholar). After removing duplicated
and nonrelevant studies, 415 studies remained.,e abstracts
of these 415 studies were screened and this resulted in the
removal of 364 studies which did not examine prescribing
patterns or determinants, thus leaving 51 studies. A further 7
studies were excluded as they were published only as con-
ference posters. In total, therefore, 44 studies remained that
examined the prescribing pattern and determinants in 17
countries and these were included in this review (Figure 2)
[41–84]. Of the 44 studies, 40% (n� 18) were undertaken in
Europe (Italy (n� 4), England (n� 2), Germany (n� 2),
Spain (n� 2), Sweden (n� 3), Norway (n� 2), whole Europe
(n� 1), Finland (n� 1), France (n� 1), and UK (n� 1)); 29%
(n� 13) were undertaken in the USA; 25% (n� 11) were
undertaken in Asia (Japan (n� 4), India (n� 3), Taiwan
(n� 2), and China (n� 1)), and 7% (n� 3) were undertaken
in other countries (Australia (n� 1), New Zealand (n� 1),
and South Africa (n� 1)). Two studies were conducted in
two diﬀerent countries at once ((USA and Japan jointly) [59]
and (Sweden and Norway jointly [84])). ,is explains why
the total of the percentages quoted above exceeds 100% (see
Tables 1 and 2). ,e results of the Kruskal–Wallis tests
indicated no signiﬁcant diﬀerences between prescribing
rates of PD medications across diﬀerent levels of study
quality scores and across the several data sources that were
used in the studies (see Table 3 and Part 5 in Supplementary
Materials). ,e only exception was L-dopa which was
prescribed signiﬁcantly more in studies which used patients’
interviews, questionnaires, or surveys compared with studies
which used insurance-claims, prescription registries, or drug
sales databases (P value� 0.011) (Table 3).
Of the 44 studies, 35 were designed to examine the
prescribing pattern of PD medications with or without
measuring prescribing determinants (Table 1) [41–48, 50, 51,
53–75, 83, 84] and 9 studies measured the prescribing de-
terminants and utilisation factors without measuring pre-
scription rates of PD medications (Table 2) [49, 52, 76–82].
,e sources of data varied according to each study design;
insurance-claims, prescription registries, or drug sales da-
tabases in 16 studies [45–47, 53, 54, 56–58, 61, 62, 64, 65, 72,
75, 81, 83]; medical charts and administrative databases in 13
studies [41–43, 48, 50, 51, 66–70, 79, 82]; patients’ interviews,
questionnaires, or surveys in 12 studies [44, 55, 59, 60, 63, 71,
73, 74, 76–78, 84]; and ﬁnally, 3 studies were designed as post
hoc studies that used previously conducted clinical trials to
ﬁnd the prescribing patterns and determinates of PD
medications (see Tables 1 and 2) [49, 52, 80]. ,e timeframe
of the studies that were reviewed was from 1986 to 2017. Out
of the studies that examined prescribing patterns, 19 were
cross sectional in design and calculated the prescription rates
of PD medications in a particular period without comparing
the rates with other periods [41–45, 48, 50, 55, 57, 60, 64, 68,
69, 71, 73–75, 83, 84] and 15 were designed to compare the
prescribing patterns in two or more diﬀerent periods [46, 47,
51, 53, 54, 56, 58, 59, 61–63, 65–67, 72]. In one study that was
conducted in Singapore, the year of the study was not
possible to establish [70]. Study settings in prescribing
pattern studies varied and included a community setting
only (n� 20) [42–44, 46, 47, 55, 57, 59, 62, 63, 65–71, 73, 75,
84], inpatient and community settings (n� 9) [45, 50, 54, 56,
58, 60, 61, 72, 74], inpatient setting only (n� 2) [41, 51],
community and care home settings (n� 2) [48, 53], in-
patient, community, and care home settings (n� 1) [64], and
ﬁnally, care home setting only (n� 1) [83]. ,e general
characteristics of the drug prescribing studies that were
reviewed are summarised in Table 1. In the prescribing
pattern studies, number of patients treated per 100,000
inhabitants, number of prescriptions, number of patients
prescribed a particular medication, deﬁned daily doses
(DDD) per 1000 inhabitants per day (DID), and number of
person-years were used as units of analysis in all studies
except one study conducted in England that used drug sales
as a unit of analysis [58]. In the studies that used the number
of patients prescribed a particular medication [41–43, 45, 47,
48, 51, 54, 55, 59–61, 66, 68–71, 73–75, 83, 84] or the number
of person-years [64] as units of analysis, the total pre-
scription rates of all PDmedications may not add up to 100%
due to the possibility that the patients were prescribed
combination therapy. On the contrary, the studies that used
the number of prescriptions or DID as units of analysis [53,
57, 62, 65, 67, 72], the total prescription rates of all PD
medications may not add up to 100% due to rounding oﬀ to
the nearest percent or due to the inability to calculate some
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Table 4: Summary of prescribing trends of PD medications and factors associated with their use.
L-dopa Dopamineagonists (DAs) COMT inhibitors MAO-B inhibitors Amantadine Anticholinergics
General
prescribing
pattern
L-dopa was the
most commonly
prescribed
medication in
most studies
regardless of the
year or the design
of the study
ranged from
37.42% (in Spain)
to 100% (in India).
Only one
Norwegian study
examined the
prescribing rate of
L-dopa intestinal
gel (LCIG).
DAs (non-ergots
mainly) were the
second most
common PD
medication
prescribed in 16
studies with the
prescription rate
ranging from
7.63% to 85%.
Studies carried out
prior to 2000
showed higher
prescription rates
of ergot DAs than
those carried out
after 2000.
,ere were no
data from most
studies regarding
apomorphine
usage.
Large variation in
the prescribing
rates of COMT
inhibitor
monotherapy
ranged from
1.01% in USA to
29% in USA as
well.
,ere were
variations in the
prescription rates
of MAO-B
inhibitors ranging
from 2.12% in
South Africa to
42% in Japan.
,ere was wide
variation, ranging
from 0.2% in Italy
to 44.23% in
Japan.
A signiﬁcant
variation was
noticed in the
cross-sectional
studies that
examined
anticholinergic
use in PD.
In some Asian
countries (India,
Japan, and
Singapore),
anticholinergics
prove more
popular with a
high prescription
rate ranging from
22.9% in
Singapore to
40.4% in India.
Trend of
prescribing
across years
,ere was an
increase in L-dopa
prescribing across
time in Sweden,
Spain, and
Europe.
A decrease in L-
dopa prescribing
across time was
observed in
Southern Italy,
Japan, USA,
Finland, and
Taiwan.
A general decrease
in prescription
rates of ergot DAs
and an increase in
the trend of non-
ergot DAs
prescription rates
were observed in
several countries
especially after
2000.
Prescribing
increase was
observed in the
USA, New
Zealand, and
Japan. On the
contrary, studies
based in Australia,
Europe, and Spain
showed a slight
decrease in
prescribing.
Selegiline
prescribing was
either maintained
or decreased
across years.
Only two studies
revealed a slight
increase of MAO-
B inhibitors
(Rasagline
mainly)
prescribed over
time in Finland
and Europe.
Across years, a
relatively steady
prescribing rate of
amantadine was
observed in the
USA, Australia,
and Europe.
A general decrease
in prescription
rates was seen in
Japan, and an
increase in the
trend of
prescription rates
was observed in
New Zealand.
Most studies have
shown a decrease
in prescription
rates of
anticholinergics
across years
Patient factors
Age
Elderly patients
(age≥ 65 years or
age≥ 70 years)
were more likely
to be prescribed L-
dopa than
younger patients.
DAs use was less
common in
elderly patients
with some
exceptions as in
some USA
hospitals.
N/A
Comparative
Italian study that
examined MAO-B
users found that
rasagiline
utilisation was
more common in
younger patients
than selegiline.
N/A
In two studies,
elderly patients
were less likely to
be prescribed or
initiated on
anticholinergics.
Gender
Multiple studies
found no
diﬀerence
between men and
women in the
likelihood of L-
dopa prescribing.
Multiple studies
found no
diﬀerence
between men and
women in the
likelihood of DAs
prescribing.
N/A
One Italian study
found that
rasagiline was
more commonly
prescribed to men
than selegiline.
N/A N/A
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Table 4: Continued.
L-dopa Dopamineagonists (DAs) COMT inhibitors MAO-B inhibitors Amantadine Anticholinergics
Race N/A
In USA, DAs
prescribing was
more common in
non-Hispanic
white people when
compared to
African
Americans,
although this
ﬁnding was not
statistically
signiﬁcant.
In USA, COMT
inhibitors
prescribing was
more common in
non-Hispanic
white people when
compared to
African
Americans,
although this
ﬁnding was not
statistically
signiﬁcant.
In USA, MAO-B
inhibitors
prescribing was
more common in
non-Hispanic
white people when
compared to
African
Americans,
although this
ﬁnding was not
statistically
signiﬁcant.
In USA,
amantadine
prescribing was
more common in
non-Hispanic
white people when
compared to
African
Americans,
although this
ﬁnding was not
statistically
signiﬁcant.
N/A
Duration of the
disease
Number of years
since PD
diagnosis was
lower in L-dopa
monotherapy
users than DAs
monotherapy
users.
Number of years
since PD
diagnosis was
lower in L-dopa
monotherapy
users than DAs
monotherapy
users.
N/A N/A N/A N/A
Comorbidities N/A
DAs prescribing
was more
common in
patients with a
high comorbidity
score.
COMT inhibitor
prescribing was
more common in
patients with a
high comorbidity
score.
MAO-B inhibitor
prescribing was
more common in
patients with a
high comorbidity
score.
Amantadine
prescribing was
more common in
patients with a
high comorbidity
score.
Patients with PD
and dementia
were prescribed
anticholinergics as
initial therapy
more commonly
than non-
dementia patients.
Socioeconomic
status and care
settings
L-dopa equivalent
daily dose (LEDD)
prescribed to care
home residents
was lower than
that prescribed to
the patients in the
community.
Patients with a
higher education
level were
prescribed DAs
more often than
patients with a
lower education
level.
Patients residing
in institutions
were less
commonly
prescribed DAs
than residents
within the
community.
COMT inhibitor
prescribing was
higher in patients
living in their
homes compared
to care homes
patients.
MAO-B inhibitor
prescribing was
higher in patients
living in their
homes compared
to care homes
patients.
N/A N/A
Geographical
location
One Norwegian
study found that
patients living in
Rogaland county
were signiﬁcantly
prescribed more
L-dopa intestinal
gel than other
counties in
Norway.
N/A N/A N/A N/A N/A
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categories of PD medication prescription rates. One ex-
ception to these rules was a study carried out in Taiwan that
used the number of prescriptions as a unit of analysis [46].
,e total prescription rates of all PD medications exceed
100% due to the fact that some prescriptions include more
than one medication. ,e prescription rates could not be
calculated for any of the PD medications in four studies [44,
50, 56, 63].
3.2. Quality of the Studies. ,e quality assessment of the se-
lected studies using the Joanna Briggs Institute Critical Ap-
praisal Tool is illustrated in Part 6 of Supplementary Materials.
Out of the prescribing pattern and determinants studies
(n� 43), two studies were given a quality score of 9 out of 10 (9/
10) [45, 49], four studies were given 8/10 [46, 54, 63, 70], seven
studies were given 7/10 [51, 56, 68, 73], six studies were given 6/
10 [48, 52, 66, 69, 71, 75], eleven studies were given 5/10
[50, 55, 57, 60, 61, 64, 65, 72], ten studies were given 4/10
[42–44, 47, 62, 67, 74], three studies were given 3/10
[41, 53, 58], and ﬁnally, one study was given 2/10 [59].
3.3. PrescribingPatterns. PDmedication prescription rates in
all the countries included in this review are presented in Part 7
of Supplementary Materials. Additionally, Table 4 shows a
grand summary of PD medications’ prescribing pattern.
3.3.1. L-Dopa. All of the studies except ﬁve [44, 48, 50, 56, 63]
calculated the prescription rate of L-dopa. Out of the studies
that calculated L-dopa prescription rates, four calculated the
prescription rates of L-dopa-carbidopa and L-dopa-carbi-
dopa-entacapone combinations separately [43, 58, 62, 84];
seven studies calculated the prescription rates of both L-dopa-
carbidopa and L-dopa-carbidopa-entacapone combinations
altogether without distinction [45, 47, 51, 57, 60, 64, 65], and
the rest of the studies calculated only L-dopa-carbidopa
prescription rates [42, 46, 53–55, 59, 61, 66–75, 83]. None of
the studies that used hospital data mentioned if LCIG pre-
scribing rate was calculated except for one Norwegian study
[41]. ,e Norwegian study found the average number of
patients using L-dopa gel to be 2.6 per 100,000 population
which was less than the number of patients using deep brain
stimulation (DBS) (2.9 per 100,000 population) [41].
Except for a few studies [53, 61, 62, 83], L-dopa was the
most commonly prescribed medication in all the studies
regardless of the year or the design of the study, accounting
for between 37.42% (in Spain) and 100% (in India) of all PD
medications [55, 67].
L-dopa prescription rates were the highest (ranging from
46.50% to 100%) compared to other PD medications in
several cross-sectional studies in Italy [73, 75], Japan [74],
Spain [71], Singapore [70], USA [45, 64, 69], Sweden and
Norway [84], South Africa [57], and India [42, 43, 55]. ,e
lowest L-dopa prescription rates were 21% in 2005 and 2008,
found in a Japanese study that used the National Japanese
Database to examine the eﬀect of pergolide withdrawal from
the USA market on PD medication prescribing patterns in
Japan by applying a time interrupted series model [61].
L-dopa did not account for the majority of prescription rates
Table 4: Continued.
L-dopa Dopamineagonists (DAs) COMT inhibitors MAO-B inhibitors Amantadine Anticholinergics
Prescribers’
factors
Type of
prescriber
In USA, half of the
family physicians
and almost one
third of the
neurologists
prescribe L-dopa
as a starting
therapy for PD
patients
immediately after
diagnosis.
In Spain, no
signiﬁcant
diﬀerence was
found in the
percentages of
prescribers of L-
dopa among
family physicians,
geriatricians,
neurologists, and
movement
disorder
specialists.
In Spain,
movement
disorders
specialists tended
to prescribe DAs
more than general
practitioners
N/A N/A
In Spain,
movement
disorders
specialists tended
to prescribe
amantadine
exclusively.
In the USA,
mental health
providers were
more likely to
prescribe
anticholinergics as
an initial therapy
than other
prescribers.
In Spain, the
percentage of
patients treated
with
anticholinergics
was higher if they
were treated by
family physicians
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in New Zealand (24.86% in 1995) [53] or Australia (36.50%
in 1995) [62]. However, both studies reported that L-dopa
prescription rates had increased and accounted for the
majority of prescribing in 2011 in New Zealand (48.76%)
and in 2009 in Australia (52.30%).
Studies carried out in other countries found an increase
in the prescription rates of L-dopa in diﬀerent years.
Figure 3(a) shows that L-dopa prescriptions increased in
Sweden, Spain, and Europe in general [65, 67, 72]. Inversely,
Figure 3(a) shows a decrease in the prescription rates of
L-dopa over the years in Southern Italy, Japan, USA, Fin-
land, and Taiwan [46, 47, 51, 54, 66].
3.3.2. Dopamine Agonists. All bar ﬁve studies calculated the
prescription rates of DAs (ergot, non-ergot, or both) [44, 50,
56, 63, 75]. Studies that calculated prescribing patterns of
DAs can be classiﬁed under studies that calculated both
ergot and non-ergot DAs prescription rates [43, 51, 53, 54,
58, 61, 62, 66, 67, 71, 73]; DAs prescription rates in general
without specifying what type of DAs [42, 45–47, 59, 60, 64,
65, 68, 69, 72, 83, 84]; ergot DAs only [70, 74]; or, non-ergot
DAs only [48, 55, 57]. Only four studies examined apo-
morphine prescribing but without specifying its pharma-
ceutical formulation forms (subcutaneous injection vs
subcutaneous infusion) [53, 62, 67, 73].
In general, DAs were the second most common PD
medication prescribed after L-dopa in 16 studies with the
prescription rate ranging from 7.63% to 85% [45–48, 51, 54,
57, 59, 64, 66, 68–71, 73, 74, 84]. Only one study that ex-
amined the pattern of prescribing in nursing homes in ﬁve
states in the USA found that DAs were the most commonly
prescribed PD medication to the members of the study
sample, surpassing even L-dopa (75% out of 10,738 PD
medications users) [83]. In small number of studies, anti-
cholinergics bumped DAs into third place, ranging from
10.90% to 29% either throughout the study, as in India [42,
43, 55], New Zealand [53], and Japan [61], or at least at one
point during the study as in Spain in 1992 [67] and Australia
in 2009 [62]. In only 1 retrospective study in Sweden, DAs
prescription rates were third after L-dopa and MAO-B in-
hibitors [72] although DA agonist prescribing continued to
grow. Aligned with the Swedish study, a gradual increase in
the trend of DAs prescription rates over the years is evident
in many countries [46, 47, 51, 53, 61, 62, 66, 67] (see Figure
4(c)). Studies from Australia, New Zealand, Spain, and Italy
revealed a slight increase in the use of apomorphine after it
became available in these countries [53, 62, 67, 73]. ,ere
were no data from other countries regarding apomorphine
usage.
(1) Ergot-Based DAs. Out of all prescribing pattern studies,
thirteen studies calculated the exact prescription rates of
ergot DAs [43, 51, 53, 54, 58, 61, 62, 66, 67, 70, 71, 73, 74].
,ere was a wide range in the prescription rates of ergot DAs
which ranged from 0.50% to 76.92%. For studies that cal-
culated the rate of prescribing at only one point of time,
there was often an association between the year of the study
and the prescription rates. For example, studies carried out
prior to 2000 showed higher prescription rates of ergot DAs
than these carried out after 2000. Studies that examined the
changes in prescription rates across a number of years found
a general decrease in prescription rates of ergot DAs [51, 53,
54, 58, 61, 67] ranging from a 3% decrease in prescription
rates in Japan between 2005 and 2008 [61] to 30.69% sales
costs decrease in England between 1999 and 2010 [58]. ,e
exception was two studies in Australia and Southern Italy
show a slight increase in ergot DAs prescription rates [62,
66]. ,e Australian study revealed an increase in ergot DAs
prescription rates from 4.10% in 1995 to 4.80% in 2009 [62]
and the Italian study found about 5% increase in the
prevalence of ergot DAs use per 100,000 inhabitants between
2003 and 2005 [66] (Figure 4(a)).
(2) Non-Ergot DAs. Fourteen studies measured the exact
prescription rate of non-ergot DAs [43, 48, 51, 53–55, 57, 58,
61, 62, 66, 67, 71, 73]. Of these, nine calculated the prescription
rates at only one time and found that the prescription rates of
non-ergot DAs ranged from 5.9% in Australia [62] to 39.80%
in South Africa [57]. An increase in the trend of non-ergot
DAs prescription rates was observed in several countries [51,
54, 58, 61, 66]. ,is increase was dramatic in some studies, for
instance in England there was a 49.2% increase in non-ergot
DAs sales rates between 1999 and 2010 [58]. Typically though,
a more modest increase in prescription rates of non-ergot DAs
was observed; for instance, in the USA (13% increase between
2001 and 2011) [51], Japan (28.2% increase between 2005 and
2010 or 5.2% increase between 2005 and 2008) [54, 61], and
Southern Italy (1.88% increase between 2003 and 2005) [66].
Although there was a general increase in non-ergot DAs
prescription rates in an American study carried out in an
inpatient setting across a number of years, the prescription rate
of non-ergot DAs decreased from 33.4% in 2008 to 27.9% in
2011 following addition of the gambling precaution (which is
one of the impulse control disorders (ICDs) forms associated
with DAs) to the pramipexole proﬁle in 2008 [51] (Figure
4(b)). Apart from the previous American study (51), only two
studies clearly stated the impact of ICDs on non-ergot DAs
prescribing and both have shown an increase in non-ergot
DAs prescribing in Taiwan (46) and England (58) which
revealed no impact of ICDs reports on non-ergots DA pre-
scribing trends.
3.3.3. COMT Inhibitors. ,e pattern of prescribing of
COMT inhibitors was examined in several studies [43, 45,
47, 51, 53–55, 57–62, 64, 65, 67, 69–73]. While only two
studies calculated the prescribing rate of the entacapone
combination (L-dopa-carbidopa-entacapone combination)
with a clear distinction between rates of L-dopa- carbidopa
and L-dopa-carbidopa-entacapone combinations [43, 84],
several studies have considered L-dopa-carbidopa and
L-dopa-carbidopa-entacapone combinations as being one
group without clear distinctions [45, 47, 51, 57, 58, 60, 64,
65]. For COMT inhibitor monotherapy, some studies cal-
culated the prescribing rates of tolcapone monotherapy [73],
entacapone monotherapy [43, 54, 55, 58, 61, 62, 67, 69, 71],
or both [39, 51, 53, 59, 64, 65, 70, 72]. COMT inhibitor
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monotherapy prescribing in the cross-sectional studies
ranged from 1.01% in the USA in 1999-2000 [69] to 29% in
the USA in 2003 [59]. An increase was observed in the USA
(2.9% in 2001 to 10.6% in 2012) [51], New Zealand (0.73% in
1998 to 3.53% in 2011) [53], and Japan (2.80% in 2007 to
8.80% in 2010) [54]. On the contrary, studies based in
Australia, Europe, and Spain showed a slight decrease in
COMT inhibitors prescribing [62, 65, 67] (Figure 3(b)).
Although a previous study in Europe found a similar de-
crease in COMT inhibitor prescribing rates, it revealed a
signiﬁcant increase in L-dopa-carbidopa and L-dopa-car-
bidopa-entacapone combination sales by 68% between 2003
and 2007. As it is accompanied by a decrease in entacapone
monotherapy prescribing over the same period, this likely
reﬂects increasing sales of L-dopa-carbidopa-entacapone
combinations [65].
3.3.4. MAO-B Inhibitors. MAO-B inhibitor prescribing
patterns were explored in the majority of the identiﬁed
studies [43, 45, 47, 48, 51, 53–55, 57–62, 64, 65, 67–73, 75,
84]. Out of the two MAO-B inhibitors available, the sele-
giline prescription rate was measured in 17 studies [53, 54,
57, 60–62, 64, 67–73, 75, 83, 84], both selegiline and rasa-
giline prescription rates were measured in 6 studies [47, 48,
51, 55, 58, 65], and the rest of the studies measured MAO-B
inhibitors as a group without specifying the name of the drug
[45, 59]. ,ere were variations in the prescription rates of
MAO-B inhibitors in the cross-sectional studies, which
ranged from 2.12% in South Africa [57] to 42% in Japan [59].
Other studies that examined changes in the trend of pre-
scription rates over the years revealed varying trends.
Selegiline prescribing was either maintained or decreased
[53, 54, 61, 62, 67, 72] (Figure 5(a)). Decreases were par-
ticularly notable in Sweden between 1995 and 2001 (28%
decrease in sales) [72] and New Zealand (18.76% in 1995 to
3.88% in 2011) [53]. A relative steady prescribing rate of
selegiline was seen in Japan [54, 61], Australia [62], and
Spain [67] (Figure 5(a)). Some studies calculated selegiline
rates in the beginning of the study and after calculating both
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Figure 3: Prescribing trends of PD medications. (a) L-dopa (without entacapone combinations). (b) COMT inhibitors.
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selegiline and rasagiline rates (as a group) when rasagiline
became commercially available [47, 51, 58, 65]. Only two
studies revealed a slight increase of MAO-B inhibitors
prescribing over time (9.90% in 2005 to 14.10% in 2012 in
Finland and 3.89% in 2003 to 5.80% in Europe) [47, 65]
(Figure 5(a)).
3.3.5. Amantadine. A total of 20 studies measured pre-
scribing rates of amantadine [42, 43, 45, 48, 51, 53–55, 57,
60–62, 64, 65, 68–71, 73, 74]. Among cross-sectional studies,
there was wide variation, ranging from 0.2% in Italy [73] to
44.23% in Japan [74]. In trend studies, a steady prescribing
rate of amantadine was observed in the USA (6.20% in 2001
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Figure 4: Prescribing trends of PDmedications. (a) Ergot dopamine agonists. (b) Non-ergot dopamine agonists. (c) All dopamine agonists.
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and 6.80% in 2012) [51], Australia (2.90% in 1995 and 3.50%
in 2009) [62], and Europe (1.86% in 2003 and 1.10% in 2007)
[65]. In Japan, 2 studies showed two diﬀerent trends, i.e.,
Nakaoka et al. found a decrease in amantadine prescribing
from 30% in 2005 to 22.10% in 2010 [54], while Ooba et al.
found no major changes between 2006 and 2008 (11% and
10%, respectively) [61]. A noticeable increase in amantadine
use was seen in New Zealand (1.26% in 1995 and 6.71% in
2011) [53] (Figure 5(b)).
3.3.6. Anticholinergics. A signiﬁcant variation was noticed
in the cross-sectional studies that examined anticholinergic
use in PD patients. Two recent studies in the USA examined
anticholinergics prescribing in inpatient and community
settings and revealed low prescribing rates of anticholin-
ergics (5% and 6.6%) [45, 64]. ,is suggests a decreasing
trend overall when compared to an earlier study (18.18%
between 1992 and 1996) [83]. In some Asian countries
(India, Japan, and Singapore), anticholinergics prove more
popular with a relatively high prescription rate ranging from
22.9% in Singapore to 40.4% in India [42, 70]. In trend
studies, most studies have shown a decrease in prescription
rates of anticholinergics across years. ,is decrease was
slight in some countries such as in USA (6.70% in 2001 to
6.10% in 2012) [51]. A more observable decrease was seen in
other countries such as in New Zealand (44.30% in 1995 to
25.44% in 2011) [53] (Figure 5(c)).
3.4. Prescribing andDrugUtilisationDeterminants. Once the
determinants of the prescription and utilisation of PD
medications are extracted, they could be classiﬁed according
to patient factors (with several subcategories) and prescriber
factors (with only one subcategory). Table 4 shows a sum-
mary of prescribing determinants of PD medications.
3.4.1. Patient Factors
(1) Age. Several studies have shown that elderly patients
(age≥ 65 years or age≥ 70 years) were more likely to be
prescribed L-dopa than younger patients [45, 47, 51, 54, 57,
60, 63, 69]. ,e L-dopa dose was inversely associated with
age in an examination of 33,534 L-dopa users in Sweden
[79]. Moreover, in two studies, elderly patients were less
likely to be prescribed [54] or initiated on anticholinergics
[68]. In contrast, with the use of L-dopa, and consistent with
guidance of preferred L-dopa use in the elderly, the use of
DAs was less common in elderly patients [45, 51]. However,
there were studies that were discrepant; Crispo et al. found
that elderly people in inpatient hospital settings in the USA
were regularly prescribed DAs, regardless of national
guidelines [51]. Studies have looked at the overall likelihood
of receiving PD medications based on age two of which
suggested that older patients (>85) were less likely to be
medicated [64, 83]. Conversely, Dahodwala et al. similarly in
the USA determined that older patients were more likely to
receive PD medications than younger patients (OR� 1.67,
95% CI, 1.17–3.27) [81].
On the contrary, a study of younger patients (≤60 years,
or ≤ 65 years) revealed a diﬀerent pattern of prescribing than
that pertaining to older patients. Younger patients were
more likely to be prescribed DAs in multiple studies and
tended to receive more than one medication to treat PD [45,
51, 79]. ,ere is signiﬁcant country to country variation in
the management of younger patients with PD with one US
study ﬁnding that the majority of younger patients in the
study were prescribed L-dopa, while only 20% of younger
patients (or ≤ 65 years) were on DAs [68]. MAO-B inhibitors
and anticholinergics were more likely to be prescribed as an
initial therapy to younger patients than L-dopa in a
Taiwanese study [56]. With regard to MAO-B inhibitors, a
comparative Italian study that examined 1607 MAO-B users
found that rasagiline utilisation was more common in
younger patients than selegiline [50]. In trend studies, a
Finnish study found that the use of MAO-B inhibitors was
increased during the duration of the study (from 2005 to
2011) in younger patients [47].
(2) Gender. Multiple studies found no diﬀerence between
men and women in terms of L-dopa and DAs prescription
rates [51, 52, 64, 66, 69]. However, where diﬀerences were
observed, they were generally indicated men receiving
higher doses or to be more likely to receive multiple
medications [45, 79, 80, 83]. ,e eﬀect of gender on the
prescribing of other types of PD medications (other than
L-dopa and DAs) was not evaluated in all the studies in this
review. However, in one study, it was found that rasagiline
was more commonly prescribed to men than selegiline, i.e.,
45.2% of selegiline users (n� 1024) and 57.8% rasagiline
users (n� 583) were men (P � 0.001) [50].
(3) Race. ,e eﬀect of patients’ race on the prescription and
general utilisation of PD medications was only evaluated in
the US-based studies. ,ese studies found that, in inpatient
and community settings, African American PD patients
were less likely to use dopaminergic medications, especially
the newer PD medications; prescribed less PD medications;
and prescribed more antipsychotics than white Americans
[78, 80, 81]. In nursing home settings, African Americans
were less likely to receive PD medications in the USA, but
this was not statistically signiﬁcant (OR� 0.89, 95% CI
0.79–1.01) [83]. Another study found that, adding medi-
cations that reduce L-dopa-induced motor ﬂuctuations
(DAs, MAO-B inhibitors, COMT inhibitors, and amanta-
dine) was more common in non-Hispanic white people
when compared with African Americans, although this
ﬁnding was not statistically signiﬁcant [82].
(4) Duration of the Disease. Some studies measured the
duration of the disease as a prescribing determinant. ,e use
of multiple PD medications was positively associated with
the duration of the disease in two studies [55, 73]. Another
study used data from a clinical trial of creatine versus
placebo in participants with early, mild PD (NET-PD LS1)
and found that the number of years since PD diagnosis was
lower in L-dopa monotherapy users than DAs monotherapy
users (1.45 years vs 1.60 years, respectively, P � 0.02) [49].
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(5) Comorbidities. Dahodwala et al. found that patients with
high morbidity scores (prescription drug hierarchical con-
dition category (RxHCC) risk score) were less likely to re-
ceive multiple PD medications (OR� 0.53, 95% CI
0.49–0.57, P≤ 0.001) [45]. Diﬀerent results were observed in
another American study that conducted a logistic regression
to ﬁnd the eﬀect of total comorbidity scores on the chance of
receiving single or multiple PD medications in elderly PD
Medicare beneﬁciaries [64]. ,e study found no association
between PDmedications use and the total comorbidity score
of patients [64]. However, the same study found that some
speciﬁc types of comorbidities might have an impact on the
chance of receiving single or multiple PD medications. For
example, patients with depression were more likely to re-
ceive PD medications than nondepressed patients
(OR� 1.25, 95% CI 1.02–1.53, P≤ 0.05) [64]. On the
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Figure 5: Prescribing trends of PD medications. (a) MAO-B inhibitors. (b) Amantadine. (c) Anticholinergics.
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contrary, patients with dementia were less likely to receive
PD medications than nondementia patients (OR� 0.62, 95%
CI 0.48–0.80, P≤ 0.001) [64]. Similar ﬁndings were observed
in nursing home setting in the USA where patients with
severe cognitive impairment were less likely to receive PD
medications than patients with normal cognitive functions
(OR� 0.79, 95% CI 0.73–0.85) [83]. Also, another study
found that patients with dementia were prescribed anti-
cholinergics as initial therapy more commonly than non-
dementia patients, but this ﬁnding was not statistically
signiﬁcant (P � 0.11) [68]. Another study revealed that the
addition of medications that reduce L-dopa-induced motor
ﬂuctuations was signiﬁcantly more common in patients with
a high comorbidity score (Charlson Index of 5 or more)
(P � 0.03) [82].
(6) Socioeconomic Status and Care Settings. All the studies
that examined the eﬀect of socioeconomic status (SES) on
PD drug utilisation were conducted in the USA and they
reported conﬂicting results. Yacoubian et al. failed to ﬁnd an
association between PD medication use and educational
level, income, and geographical residence of the patients
[80]. Another study found no association between PD
medication use and income and marital status of the patient
[64]. However, the same study revealed that the chance of
being prescribed any of the PD medications was higher for
patients with a higher education level (high diploma or
more) than patients with a lower education level patients
(OR� 1.51, 95% CI 1.04–2.19; P< 0.05) [64]. Hemming et al.
found no diﬀerence in the use of PD medications across
patients with diﬀerent levels of income and educational level
except for the fact that these with lower income and/or a low
education level were less likely to be prescribed newer PD
medications and were more likely to be prescribed anti-
psychotics [78]. Another study found that patients with a
higher education level were prescribed DAs more often than
patients with a lower education level [49]. With regard to the
eﬀect of health insurance on prescriptions, one study carried
out in the USA conﬁrmed that PD patients without health
insurance received fewer PD medications than patients who
had health insurance of any type (P � 0.0011) [80].
Regarding patients’ care settings, an American study
found that only 44% of a total of 24,402 nursing home
residents with PD in the USA received PD medications [83].
Another US study based on Medicare claims for PD patients
from 2000 to 2003 revealed that patients residing in in-
stitutions were more likely to receive PD medications than
residents within the community (OR� 1.78, 95% CI 1.17–
2.71; P< 0.01) [64]. ,e same study found that patients
residing in institutions were less commonly prescribed DAs
than residents within the community (15.7% vs 35%, re-
spectively) (P< 0.001 [64]. In the UK, Hand et al. compared
PD medication use in the community vs care homes in a
retrospective study using,e Northumbria Healthcare NHS
Foundation Trust PD service in England [48]. ,ey found
that the L-dopa equivalent daily dose (LEDD) prescribed to
care home residents was lower (median LEDD� 400mg,
95% IQR 250–610) than that prescribed to the patients in the
community (median LEDD� 657.5mg, 95% IQR 447.5–
1048) (P< 0.001) [48]. ,e same study found that use of
DAs,MAO-b inhibitors, and COMTinhibitors was higher in
patients living in their homes [48].
(7) Geographical Location.,is factor has been examined
only in one Norwegian study that found that patients who
live in Rogaland county were prescribed signiﬁcantly more
L-dopa intestinal gel than other counties in Norway [41].
,is diﬀerence was attributed in the study to the amount of
knowledge patients had about the advanced therapy options
in Norway [41].
3.4.2. Prescribers’ Factors
(1) Type of Prescriber. Eleven studies examined the associ-
ation between prescriber type and prescribing pattern of PD
medications [45, 56, 59, 62, 63, 68, 70–72, 76, 82]. Prescribers
in these studies could be classiﬁed as general practitioners
(GPs), family physicians, mental health providers, geria-
tricians, neurologists, and movement disorders specialists.
A US survey evaluating 54 family physicians, 328 neu-
rologists, and 74 movement disorder specialists, determined
that half of the family physicians and almost one-third of the
neurologists prescribe L-dopa as a starting therapy for PD
patients immediately after diagnosis [59]. While in Spain, no
signiﬁcant diﬀerence was found in the percentages of pre-
scribers of L-dopa among family physicians, geriatricians,
neurologists, and movement disorder specialists (87.3%,
86.1%, 91.2%, 91.9%, respectively) [71] although movement
disorders specialists tended to prescribe DAs more often and
exclusively prescribed amantadine [71]. In USA, family
physicians were more likely to prescribe L-dopa, while
neurologists and movement disorder specialists were more
likely to prescribe DAs [68]. Likewise, in Australia, around
80% of the total DID of L-dopa was prescribed by family
physicians while 10% to 20% was prescribed by neurologists
with minimal variation between 2003 and 2009 [62].
In the USA, mental health providers were more likely to
prescribe anticholinergics as an initial therapy than other
prescribers (OR� 76, 95% CI 31.7–181.7) [68], whilst in
Spain, the percentage of patients treated with anticholin-
ergics was higher if they were treated by family physicians
(17.8%) as opposed to geriatricians (11.1%), neurologists
(8.6%), or movement disorder specialists (7%) [71].
Polytherapy and therapy switching were another two
issues that only a few studies examined. In USA, Dahodwala
et al. found that patients who were treated by neurologists
were more likely to receive multiple PD medications than
patients who were treated by others (non-neurologists) [45].
In a study in Taiwan that examined the type of initial therapy
in PD patients from 2000 to 2010, it was found that 79.3% of
L-dopa and DAs combination therapy was initiated by
neurologists and 20.7% was initiated by non-neurologists
[56].,e same study noted that patients who were treated by
neurologists were more likely to be switched to another drug
within one year of the study [56].
,e impact of the type of prescriber on adherence to
national guidelines was another parameter that was evalu-
ated in two studies [63, 76]. ,e French study failed to ﬁnd a
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signiﬁcant diﬀerence between neurologists and non-neu-
rologists in adherence to the type of initial therapy that was
recommended in French treatment guidelines of PD in 2000
[63]. Conversely, the Chinese study found that movement
disorders specialists were more successful than GPs and
general neurologists in improving a patient’s quality of care
and adhering to Chinese national guidelines that included
several recommendations on how to reduce L-dopa-induced
motor ﬂuctuations by adding COMT inhibitors, MAO-B
inhibitors, or others [76]. Likewise, Cheng et al. found that
prescribing medications that reduced L-dopa-induced
motor ﬂuctuations was more commonly done by movement
disorders specialists than general neurologists and GPs in
the USA [82].
4. Discussion
,e number of PD-related drug utilisation studies identiﬁed
for review in this study was limited, taking into account the
non-negligible prevalence of PD [85, 86]. Most of the studies
that were included were conducted in the USA and Europe
(68% of all studies) which have limited the geographical
spread. ,is may relate to the high prevalence of PD cases in
these countries, exempliﬁed by a recent meta-analysis ex-
amining 47 prevalence studies globally, determining that PD
prevalence was higher across all ages in Europe, North
America, and Australia than in Asia [85]. However, in terms
of prevalence, South America surpassed them all [85] but no
drug utilisation study in South America was identiﬁed for
review.
,e source of drug utilisation data varied in the reviewed
studies, with 38% of the data being sourced from insurance-
claim, prescription registry, or drug sales databases. Data
sourced from insurance-claims or similar sources may in-
clude a large number of patients which makes it possible to
generalise the study results to the whole population but it is
also highly possible that these databases include patients
who have other diseases that have mistakenly been di-
agnosed as PD (e.g., secondary parkinsonism) since these
data lack detailed patient clinical information. Several
studies that used this source of data that were included in
this review acknowledged this drawback and considered the
possibility of over estimation of PD medication prescribing
rates [45, 46, 54, 56, 64, 81, 83]. About 26% of the studies
reviewed here used patient interviews, questionnaires, and
surveys to estimate drug utilisation rates. Although this
approach might give a more accurate estimate of medication
prescribing patterns, given that the data are based on a more
accurate diagnosis by PD experts [43, 44, 63], the relatively
small sample sizes restricts the generalisability of the ﬁnd-
ings. Use of electronic medical records (EMRs) and GP data
may overcome the problems of small sample size and
misdiagnosis in drug utilisation studies. However, to avoid
the inherent drawbacks of EMR (missing data and data entry
errors), it is essential to validate these electronic medical
records against standard criteria such as the actual paper ﬁles
of the patients, GP questionnaires, or linking data to other
databases [87, 88]. Of all the studies that used EMR and GP
data included in this review (28%), none were validated
against standard criteria. However, in general, the impact of
source of data on PD medications prescribing was minimal
in most studies. ,e exception was L-dopa which was re-
portedly more prescribed than other PD medications in
studies using interviews, questionnaires, and surveys in their
methodology. However, this increase is most likely due to
the time of these studies (most of them were conducted
before 2000), when the current portfolio of dopaminergic
drugs was either not clinically available or eﬃcacy was not
well-established (Part 5 in Supplementary Materials).
,erefore, no valid conclusion could be drawn from a simple
comparison of L-dopa prescribing according to the source of
data.
In the majority of studies, regardless of the study year or
location, unsurprisingly L-dopa plus a dopa decarboxylase
inhibitor (carbidopa or benserazide) persists as the most
commonly prescribed PD medication, (with or without the
COMT inhibitor, entacapone), with no signiﬁcant changes
over time. Where an increase was identiﬁed over time (New
Zealand, Australia, Sweden, and Spain) [53, 62, 67, 72], this
was hypothesised to be due to an increase in PD incidence,
an increase in the duration of the disease, or an increasing
preference for L-dopa therapy over DAs in the early stages of
the disease. Determining which cannot be identiﬁed from
this data but a real increased PD incidence is unlikely. We
had anticipated that some trends might have evidenced the
changing recommendations in DA vs L-dopa use. In the
early 2000s, multiple studies reported that long-term L-dopa
could contribute to neurotoxicity [89, 90]. ,e ELLDOPA
trial in 2004 [91] refuted these ﬁndings, and the American
Academy of Neurology (AAN) guidelines in 2006 used this
evidence to state that L-dopa did not accelerate disease
progression [92]. ,ere was vigorous debate in the ﬁeld at
this time on the beneﬁts of commencing therapy with DA
agonists to delay onset of L-dopa-induced dyskinesia (LID)
and other potential beneﬁts of reduced development of LID
we anticipated might have altered prescribing but this was
only evident in marginal trends [93, 94]. Recently, the LEAP
study revealed that L-dopa has no disease-modifying eﬀects
[95]; however, the high reliance on L-dopa could be
explained by its higher eﬃcacy and better safety proﬁle than
other PD medications [96, 97]. Indeed, the PD-MED study
only supported part of this rational used the QoL scale and
determining that initiating patients with L-dopa actually
resulted in a better QoL than using DAs and that reducing
motor ﬂuctuations by delaying L-dopa initiation was not
associated with better results over the long term [32].
In this review, there was a noticeable paucity of studies
examining the prescribing of advanced infusion therapies in
advanced PD patients. For LCIG, there was only one study
that examined its prescribing rates in advanced stages of PD
[41]. LCIG is an intestinal infusion pump, which aims to
avoid the motor complications caused by oral L-dopa, by
oﬀering more continuous dopaminergic stimulation and
constant levels of plasma levodopa [17]. However, the
promising eﬃcacy of LCIG [17] and its improvement to
QOL [98] could be hindered by the high cost, invasive nature
of the LCIG pump, and possible complications at the in-
fusion site [17]. ,erefore, it is of importance to investigate
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the actual pharmacoepidemiological use of this kind of
therapy and the factors that determine its prescribing in
future research. It is of importance also to conduct more
research on the prescribing of the second type of advanced
therapy, apomorphine, since very few studies identiﬁed
report its prescribing, and those that do fail to specify its
pharmaceutical forms.
Early reports of potential neuroprotective eﬀects of DAs
may have contributed to a general increase in DAs pre-
scribing in the early 2000s [99–103], but in 2006, the AAN
report stated that there was no evidence of neuroprotection
for DAs [92] and subsequent reports and clinical trials
conﬁrmed the AAN recommendation [17, 20, 22, 103, 104].
,ese reports might explain why some studies found a slight
decrease in the prescription of DAs especially after 2005
[51, 54]. ,e slight increase or consistent rate in prescribing
DAs is seen in other studies [47, 53, 56, 61, 62] which might
be due to the fact that DAs were still the recommended
treatment in the guidelines as a starting therapy especially
with younger patients [105–107]. Recently, the UK NICE
guidelines recommended starting therapy with DAs or other
dopaminergic therapies (MAO-B inhibitors or L-dopa) in
the early stages of PD if the motor symptoms do not impact
patients’ quality of life [108].
Within the subtypes of the DAs, several cross-sectional
studies have shown a wide range of ergot DAs prescription
rates.,e relatively high prescribing rate seen in the studies
conducted before 2000, may be due to the cumulative eﬀect
of reports of L-dopa neurotoxicity in the late 1990s and
early 2000s [89, 90], the hope that ergot DAs might possess
neuroprotective properties [102, 109, 110], and the fact that
ergot DAs side eﬀects, such as cardiac ﬁbrosis, had not yet
been discovered. In the trend studies, most showed a de-
crease in the prescription of ergots even though the results
of a large-scale UK study that led to a voluntary withdrawal
of this drug from the US and Canadian markets in 2007 had
not yet been published [111, 112]. For example, in the USA,
there was a 5.1% decrease in the prescription of ergots
between 2001 and 2007 [51]. ,e same phenomenon was
seen in New Zealand, Japan, Italy, and Spain, in parallel
with an increase in non-ergot DAs prescription
[53, 54, 66, 71]. An association between the use of ergot
DAs (pergolide initially) and valvular heart toxicity was
reported in the early 2000s [113]. Whilst non-ergot DAs
might have seemed an obvious alternative, reports then
emerged of side eﬀects associated with their use [114–118].
Although in several studies the non-ergot prescription
rate increased, particularly after pergolide withdrawal
[46, 47, 51, 53, 54, 62], the prescription rates decreased in
the USA in 2011 [51]. ,is could be explained by reports of
several side eﬀects of non-ergot DAs that appeared between
2006 and 2017. Examples of these side eﬀects, in addition to
reports of the risk of heart failure associated with prami-
pexole, include ICDs [119]. ICDs in this context are typiﬁed
by a failure to resist the urge for sexual intercourse,
gambling, and eating, and it is evident from the DO-
MINION study that ICDs are signiﬁcantly associated with
DAs [120]. It is disappointing that, despite the increase
in recognition ICDs among DAs users, most studies
conducted in the last 10 years did not mention the impact
of ICDs on DAs prescribing. It will be important to conduct
further studies to explicitly examine whether increased
awareness of ICDs among prescribers and patients has had
an eﬀect on their prescribing.
Prescribing rates of COMT inhibitors were largely con-
sistent with both slight increase [51, 53, 54] and slight decrease
[62, 65, 67] reported. In some studies, diﬀerentiating the exact
prescription rate of COMT inhibitors without considering the
L-dopa prescription rate is diﬃcult since the prescription rate
of the L-dopa+ carbidopa+ entacapone combination was re-
ported in the studies but not the rate of entacapone alone
[45, 47, 51, 57, 58, 60, 64, 65]. Tolcapone monotherapy was
explicitly measured in one study in Italy in 1997-1998 and
showed a very low prescription rate (1.3% of the total pre-
scriptions) [73] which is likely linked to the FDA black box
warning about the hepatotoxicity risk in 1998 [121] and its very
recent approval. Post 2000, any increase in entacapone plus
tolcapone prescription rates as in the USA [51] and New
Zealand [53] might have been due to entacapone alone since
tolcapone prescriptions were restricted due to its hepatotox-
icity. No conclusion could be drawn regarding the prescription
rates of the L-dopa+ carbidopa+ entacapone combination in a
number of the studies which did not distinguish between its
prescription rate and the L-dopa+ carbidopa combinations
prescription rate [45, 47, 51, 57, 58, 60, 64, 65].
Although it was still in clinical trials testing for possible
neuroprotective properties after its approval in 2006, the
prescription rate for rasagiline (an MAO-B inhibitor) was
only examined in six of the studies [47, 48, 51, 55, 58, 65]
whilst the prescription rate for selegiline was highly varied
between studies [53, 54, 57, 60–62, 64, 67–73, 75, 83, 84].,e
decrease in prescribing around 1995 can be linked to the
PDRG-UK trial which suggested association with an in-
creased mortality rate [122], although was subsequently
debated by a meta-analysis [123]. Furthermore the decline in
use has continued with the purported neuroprotective
properties suggested by a range of clinical trials (TEMPO
[18], ADAGIO [19]) being unsupported by the guidance
[108]. Saﬁnamide is an MAO-B inhibitor that has been
recently approved as an add-on therapy to L-dopa in pa-
tients who develop motor ﬂuctuations and with its relatively
recent appearance its place on the PD stage has yet to evolve
signiﬁcantly.
A huge variation in amantadine prescription rates can be
seen, which is characterised by very low and consistent rates
in all but Japan for which there is no explanation [54].
Unlike other PD medications, amantadine has not been
subjected to signiﬁcant changes in safety or eﬃcacy proﬁles
since the Schwab trail in 1969 that suggested the clinical
eﬃcacy of amantadine in treating PD symptoms [3]. ,e
main indication for amantadine, based on Schwab’s work,
was to treat the early symptoms of PD, but this was not
enough to avoid adding or switching to L-dopa therapy in
the long run [124]. In the late 1990s, several studies showed
the antidyskinetic eﬀect of amantadine to treat L-dopa-in-
duced dyskinesia [125, 126]. In 2017, the extended release
form of amantadine was the ﬁrst medication that was ap-
proved by the US FDA to treat L-dopa-induced dyskinesia
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[127]. How this formulation and approval aﬀects prescribing
remains to be seen moving forward.
Anticholinergics were routinely used in the treatment of
PD before the discovery of L-dopa; however, due to their
troublesome side eﬀects, their use is limited at present to
managing severe tremor in younger patients who do not
suﬀer from cognitive problems [128]. Notwithstanding this
fact, anticholinergic prescription rates were generally high in
most Asian studies [42, 43, 54, 55, 61, 70] but is generally
reducing over time through replacement with other strat-
egies. ,is was explained, for example, in one Japanese study
by the fact that the treatment guidelines in Japan in the early
2000s recommended anticholinergics as the ﬁrst option [54].
An Indian study attributed this high rate of prescribing
anticholinergics to the fact that they were cheaper than most
of the other PD medications in India [43]. In the USA, two
cross-sectional studies showed a very low rate of anticho-
linergics prescriptions possibly reﬂecting an awareness of
anticholinergics side eﬀects especially in older patients
[45, 64]. Conversely, Lapane et al. found a high rate of
anticholinergics prescriptions (18.18%) in nursing home
settings in the USA [83]. ,ese data are confounded by the
use of anticholinergics in neuroleptic-induced parkinsonism
and other conditions.
4.1. Prescribing Determinants. Age was one of the most
common factors that aﬀects the use of PD medications. In a
number of studies, older patients were less likely to receive
PD medications than younger patients, likely to be linked to
fear of side eﬀects, interactions, or increased morbidity. ,is
is consistent with ﬁndings that old age in general has a
positive association with high morbidity scores in people
with Parkinson’s [129].
Whilst L-DOPA has been demonstrated to be the most
eﬀective medication for all age groups in PD [130], several
studies demonstrated a clear preference for younger patients
to be prescribed DA agonists, withdrawing them in older
people, consistent with the guidelines. L-dopa causes fewer
side eﬀects than DAs in elderly people [131] and DAs are
three times more likely to cause hallucinations than L-dopa
[132, 133]. Additionally, DAs cause a higher rate of som-
nolence and sleep attacks [132, 133] and could signiﬁcantly
more likely trigger ICDs such as hypersexuality and path-
ological gambling [134, 135]. However, notwithstanding
these recommendations, Cirspo et al. found that, in inpatient
settings in the USA, there was a continuous high rate of
prescription of DAs for elderly patients, which raised a
question regarding the awareness of treatment guidelines
[51]. In relation to the L-dopa dose given, a Swedish study
found that older patients were associated with a lower
L-dopa dose than younger patients [79] which may be due to
the pharmacokinetics (L-dopa has a greater bioavailability
and less clearance volume in elderly people [136, 137]).
Overall, according to the studies included in this review,
it seems that the several guidelines published after 2000
[28, 107, 138] recommending starting therapy with DAs or
MAO-B inhibitors in younger patients and starting L-dopa
in older patients might have had an impact on clinical
practice. However, according to the results of the PD-MED
study, the recent NICE guidelines did not consider age as a
factor in choosing the ﬁrst-line treatment. Patients’ quality
of life, instead, was the major factor that aﬀected the
treatment decision. According to the NICE guidelines, if
motor symptoms do not aﬀect patients’ quality of life, then
starting therapy with DAs or other dopaminergic therapies
(MAO-B inhibitors or L-dopa) is recommended [108].
L-dopa, on the contrary, should be used if motor symptoms
aﬀect the patients’ quality of life [109].
Gender was examined in multiple studies but with
conﬂicting outcomes. Whilst several studies found no
gender relationship in L-dopa and DAs prescription rates
[51, 52, 64, 66, 69], others found that women had lower odds
of being prescribed L-dopa [45], were less likely to receive
PD medications (both polytherapy and monotherapy)
[45, 80, 83], and the L-dopa daily dose was lower for women
[79]. Whilst this may be linked to the pharmacokinetics, this
is under research and does require more investigation into
the diﬀerences in responses between medications and sen-
sitivity to side eﬀects.
In most countries, the patients’ race was not investigated
as a factor inﬂuencing prescription. However, a few studies
in USA revealed inequalities relating to African Americans
when it comes to PD medication prescriptions, particularly
with regard to the newly approved medications, which are
generally more expensive [78, 80–83]. Similar inequalities
exist across broad tranches of the US healthcare system in
relation to PD [139, 140] and other conditions which may be
linked to African Americans in general are less likely to have
medical insurance and have less access to healthcare facilities
than white Americans in the USA [141].
Residence in long-term care facilities such as care homes
can be a factor aﬀecting access to health care in PD patients.
One study, that included a large number of PD patients in
care home settings in the USA, found that about 56% of
patients did not receive any PD medication [83]. ,e study
did not consider this phenomenon as a sign of health in-
equality; rather, it suggested that these patients had most
likely been admitted to nursing homes due to debilitating
side eﬀects, i.e., psychosis caused by PD medications. ,is
claim was supported by Hand et al. who compared PD
medication use in the community vs care homes in England
and found that LEDD was lower in care home residents than
patients in the community [48]. Although there is a dif-
ference in the endpoints of the two previous studies, i.e., the
ﬁrst study examined any single use of PD medication [83]
while the second measured the total dose of PD medications
taken [48], both reached the same conclusion. According to
the two studies, the reason behind the lower use or lower
dose of PD medications in care homes was to avoid psy-
chotic episodes caused by PD medication. In PD patients,
psychosis can occur as a consequence of the disease itself, or
it can be caused by the PD medications [142]. ,us, it is
crucial, when managing psychosis in PD patients, to titrate
ﬁrstly the PD medication doses before considering pre-
scribing antipsychotics [143]. Despite previous evidence that
attributed the lack of PD medication utilisation in care
homes to a plausible clinical reason, i.e., to avoid the side
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eﬀects of PD medications, some studies found inappropriate
management for PD patients in care homes [83, 144]. ,is
could be explained by lack of access to secondary clinics or
switching to a new GP which resulted in suboptimal care
[145]. Telemedicine (the approach that uses new technology
such as video teleconferencing to link health care providers
to PD patients directly) is one tool that could potentially
resolve the issue of lacking access to health care due to
diﬃculty accessing health care facilities [146].
Among the countries covered in this review, there were
diﬀerences in health care systems, prescribing guidelines and
in the eligibility of the patients, which limit the value of
making comparisons between countries. However, there
were some common observations that are worth mentioning
in relation to the prescribers themselves. In the only studies
identiﬁed, movement disorders specialists and neurologists,
more than family physicians or GPs, were more likely to
prescribe DAs according to some of the studies [62, 68, 71],
whereas family physicians and GPs were more likely to
prescribe L-dopa or anticholinergics [62, 71]. Since these
studies predate many of the changes in guidance, more up-
to-date examination of the relative roles and trends in
prescribing would be valid.
,is study has several limitations. First, the reviewed
studies were heterogeneous in terms of design, duration,
and data sources. ,is makes direct comparisons of the
prescription rates of diﬀerent PDmedications very diﬃcult.
,is type of diﬃculty has been previously identiﬁed in
other studies [147, 148]. Second, although quality scores
were assigned to each study, no study was excluded on the
basis of its quality score due to lack of evidence. However,
the study score might indicate its quality level. Future
studies should focus on developing a quality assessment
tool that would help researchers make decisions in drug
utilisation research.,ird, the fact that this review included
only English studies could introduce language bias.
However, we tried to minimize this bias by identifying
relevant non-English-language studies in our literature
searches. ,e fourth limitation was the assumption that has
been made in the discussion section which has attributed
the changes in prescribing patterns of PD medication to
awareness or nonawareness of the guidelines. Other factors
such as drug availability and patient preferences might
explain some prescribing behaviours. ,erefore, caution
should be taken when interpreting the results reported in
this review.
5. Conclusions
In conclusion, worldwide, since the discovery of L-dopa, it
has been themost commonly prescribed PDmedication.,e
prescription rates of ergot-derived DAs decreased in several
countries due to cardiac toxicity issues, while the use of non-
ergot DAs increased. Signiﬁcant country to country varia-
tion in the prescribing rates of COMT inhibitors, MAO-B
inhibitors, amantadine, and anticholinergics was found.
Alongside this, patient age was the most common factor that
aﬀected prescribing in most studies. ,e most recent 3rd
generation MAO and COMT inhibitors have not been
considered in any study as they are so new to the portfolio
and new guidance has recently been released in the UK.
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